Reagent unit for testing chlamydia fastly and its production

Abstract

A kit for quickly detecting Chlamydia is prepared as forming reagent bar by water absorption paper, nitrocellulose filter, glass fiber paper sheet and sample filtering paper. Its detecting method includes using Chlamydia infected on human body as detection object substance such as swab specimen of female cervix or male urethra mycoderma cell and swab specimen of eye conjunctiva cell, carrying out color developing reaction on said specimen by said reagent bar then observing result by eyes.

Description

1. Technical field: [0001] The invention relates to a kit for rapidly detecting chlamydia by using anti-chlamydia lipopolysaccharide (LPS) monoclonal antibody and colloidal gold immunochromatography technology and a preparation method thereof. 2. Background technology: [0002] Chlamydia is a pathogenic microorganism that causes human urethritis, cervicitis, pneumonia and trachoma, etc., and has serious harm. Genetically, there are three main types: Chlamydia Trachomatis, Chlamydia Psittas and Chlamydia Pneumoniae. Among them, Chlamydia trachomatis is one of the main pathogenic microorganisms that cause infection of the human genitourinary system, and is one of the main pathogenic microorganisms of sexually transmitted diseases. In the United States, about 4 million new cases of chlamydia infection occur every year. In the sexually promiscuous and sexually active normal families in developing countries, the infection rate of chlamydia trachomatis in the genitourinary tract ...

AI Technical Summary

Problems solved by technology

In secretion samples, the detection samples are cell secretions, not mucosal cell swabs, so the sensitivity of detecting chlamydia is poor

[0008] There are related patents related to similar detection methods of chlamydia antigens in China, such as application number 01131835.X. The technical defects of this patent are: first, there is no relevant monoclonal antibody screening process, and the quality of monoclonal antibodies cannot be guaranteed; second, the detection of samples It is a secretion, not a mucosal cell swab, so the detection sensitivity is poor

Application No. 02116407.X, the technical defect of this patent is: use the mixed primary body of Chlamydia trachomatis (EBS) as the antigen to immunize mice to prepare monoclonal antibody, and the primary body of Chlamydia trachomatis (EBS) is used as the complete bacterium, and use it as the Immunogens will obtain very complex antibody cell lines, which is not conducive to the establishment of monoclonal cell lines, and the screened antibodies have many cross-reactions and poor specificity

Application No. 03112265.5, the technical defect of this patent is: although the specific chlamydia lipopolysaccharide (LPS) used in this technology is used as an antigen to immunize animals, the animal is directly purified to prepare the antibodies required for the production of chlamydia detection kits, instead of using the anti-chlamydia LPS single cloned antibody

Obviously, the antibody obtained by this method is a mixture and a polyclonal antibody, so the specificity is poor